D.A. Davidson & CO. Purchases 6,507 Shares of Amgen Inc. (NASDAQ:AMGN)

D.A. Davidson & CO. increased its position in Amgen Inc. (NASDAQ:AMGN) by 3.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 224,241 shares of the medical research company’s stock after acquiring an additional 6,507 shares during the period. D.A. Davidson & CO.’s holdings in Amgen were worth $58,446,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of AMGN. Wealth Quarterback LLC raised its holdings in shares of Amgen by 7.6% during the fourth quarter. Wealth Quarterback LLC now owns 1,733 shares of the medical research company’s stock valued at $452,000 after purchasing an additional 123 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in shares of Amgen by 10.2% in the fourth quarter. CIBC Asset Management Inc now owns 369,511 shares of the medical research company’s stock worth $96,309,000 after buying an additional 34,299 shares during the last quarter. Woodard & Co. Asset Management Group Inc. ADV increased its holdings in Amgen by 2.2% during the fourth quarter. Woodard & Co. Asset Management Group Inc. ADV now owns 10,494 shares of the medical research company’s stock valued at $2,735,000 after buying an additional 222 shares during the last quarter. KLCM Advisors Inc. raised its position in Amgen by 23.0% in the fourth quarter. KLCM Advisors Inc. now owns 1,160 shares of the medical research company’s stock worth $302,000 after acquiring an additional 217 shares during the period. Finally, Nicholas Hoffman & Company LLC. boosted its stake in shares of Amgen by 13.6% during the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,173 shares of the medical research company’s stock worth $306,000 after acquiring an additional 140 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN opened at $291.16 on Tuesday. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The business has a fifty day moving average of $274.12 and a 200 day moving average of $301.42. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The stock has a market cap of $156.51 billion, a P/E ratio of 38.56, a PEG ratio of 3.01 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.27%. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is 119.21%.

Analyst Ratings Changes

AMGN has been the topic of a number of recent research reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Redburn Partners reduced their target price on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Finally, Piper Sandler upped their price target on shares of Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $314.09.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,405 shares of company stock worth $10,410,596 in the last ninety days. 0.69% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.